INVIVYD, INC. Earnings Per Share, Basic and Diluted
INVIVYD, INC. (IVVD) reported Earnings Per Share, Basic and Diluted of -$0.93 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-13
- INVIVYD, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.93.
- INVIVYD, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.77.
- INVIVYD, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.98.
- INVIVYD, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$178.86.
- INVIVYD, INC. earnings per share, basic and diluted for fiscal 2021 was -$5.32.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 7 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$0.93 10-Q · filed 2022-05-13 | -$1.71 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.65 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$4.17 derived: net income ÷ weighted average shares · filed 2023-11-09 | |
| 2021-12-31 | -$0.77 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.70 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.34 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$5.32 10-K · filed 2022-03-31 | |
| 2021-09-30 | -$0.98 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$3.41 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$7.06 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$7.06 derived: net income ÷ weighted average shares · filed 2022-03-31 | |
| 2021-06-30 | -$178.86 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$663.94 derived: net income ÷ weighted average shares · filed 2022-08-15 | -$663.94 derived: net income ÷ weighted average shares · filed 2022-03-31 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | ||||
| 2020-12-31 | -$18.10 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$25.98 derived: net income ÷ weighted average shares · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |